Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation: A Multicenter Study.
暂无分享,去创建一个
I. König | A. Rahmel | P. Reinke | D. Stippel | B. Banas | K. Budde | W. Arns | U. Eisenberger | M. Ziemann | N. Heßler | N. Lachmann | V. Ditt | A. Habicht | L. Renders | F. Sommer | S. Görg | M. Nitschke | T. Feldkamp | F. Heinemann | K. Angert | M. Koch | C. Kurschat | A. Mühlfeld | C. Süsal | B. Spriewald | C. Hugo | G. Einecke | T. Bakchoul | T. Rath | D. Zecher | W. Altermann | B. Thiele | M. Marget | M. Guthoff | A. Bachmann | T. Kauke | C. Quick | O. Staeck | M. Hallensleben | A. von Borstel | M. Kaufmann | C. Lehmann | Luiza Pego da Silva | M. Guthoff
[1] D. Roelen,et al. Pretransplant Donor-Specific Anti-HLA Antibodies and the Risk for Rejection-Related Graft Failure of Kidney Allografts , 2020, Journal of transplantation.
[2] S. Jordan,et al. Clinical and Public Policy Implications of Pre-Formed DSA and Transplant Outcomes. , 2019, Clinical journal of the American Society of Nephrology : CJASN.
[3] J. Jung,et al. Impact of pretransplant donor‐specific antibodies on kidney allograft recipients with negative flow cytometry cross‐matches , 2018, Clinical transplantation.
[4] M. Schoenberg,et al. Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months , 2018, PloS one.
[5] M. Bots,et al. Differential effects of donor‐specific HLA antibodies in living versus deceased donor transplant , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[6] S. Hariharan,et al. Anti-CD20 Blocker Rituximab in Kidney Transplantation , 2018, Transplantation.
[7] S. Jordan,et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. , 2017, The New England journal of medicine.
[8] N. Goto,et al. Favorable results in ABO‐incompatible renal transplantation without B cell‐targeted therapy: Advantages and disadvantages of rituximab pretreatment , 2017, Clinical transplantation.
[9] M. Stegall,et al. Kidney Transplant With Low Levels of DSA or Low Positive B-Flow Crossmatch: An Underappreciated Option for Highly Sensitized Transplant Candidates , 2017, Transplantation.
[10] C. Nast,et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation , 2017, The New England journal of medicine.
[11] Ji Hyun Yu,et al. Clinical outcomes of ABO‐ and HLA‐incompatible kidney transplantation: a nationwide cohort study , 2017, Transplant international : official journal of the European Society for Organ Transplantation.
[12] I. König,et al. Unacceptable human leucocyte antigens for organ offers in the era of organ shortage: influence on waiting time before kidney transplantation , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[13] X. Jouven,et al. Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. , 2017, Journal of the American Society of Nephrology : JASN.
[14] D. Dimova,et al. One hundred ABO-incompatible kidney transplantations between 2004 and 2014: a single-centre experience. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[15] W. Arns,et al. Determination of unacceptable HLA antigen mismatches in kidney transplant recipients: recommendations of the German Society for Immunogenetics. , 2015, Tissue antigens.
[16] E J Steenbergen,et al. Rituximab as Induction Therapy After Renal Transplantation: A Randomized, Double‐Blind, Placebo‐Controlled Study of Efficacy and Safety , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[17] Martin Zeier,et al. Three-Year Outcomes Following 1420 ABO-Incompatible Living-Donor Kidney Transplants Performed After ABO Antibody Reduction: Results From 101 Centers , 2015, Transplantation.
[18] M. Stegall,et al. Quantifying the Risk of Incompatible Kidney Transplantation: A Multicenter Study , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[19] X. Jouven,et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. , 2013, The New England journal of medicine.
[20] R. Montgomery,et al. Rituximab Prevents an Anamnestic Response in Patients With Cryptic Sensitization to HLA , 2013, Transplantation.
[21] A. Webster,et al. Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation , 2013, Transplantation.
[22] L. Ratner,et al. Donor-specific antibodies adversely affect kidney allograft outcomes. , 2012, Journal of the American Society of Nephrology : JASN.
[23] Nathan T. James,et al. Outcomes of ABO-Incompatible Kidney Transplantation in the United States , 2012, Transplantation.
[24] M. Mihatsch,et al. Efficacy of Induction Therapy with ATG and Intravenous Immunoglobulins in Patients with Low‐Level Donor‐Specific HLA‐Antibodies , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[25] Douglas E Schaubel,et al. A Comprehensive Risk Quantification Score for Deceased Donor Kidneys: The Kidney Donor Risk Index , 2009, Transplantation.
[26] A. Webster,et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data , 2005, BMJ : British Medical Journal.
[27] P. Terasaki,et al. Significance of the positive crossmatch test in kidney transplantation. , 1969, The New England journal of medicine.